The increasing prevalence of nontuberculous mycobacteria (NTM) infections worldwide poses significant public health challenges, underscored by high fatality ...

According to the American Lung Association, the number of people living with Nontuberculous Mycobacterial (NTM) lung disease is on the rise, especially among women and older age groups. This bacterial ...

MannKind’s future hinges on Tyvaso DPI's growth, R&D prospects, and financial stability despite competition and risks.

Shares of MannKind Corporation jumped over 7% in after-hours trading after the biopharmaceutical company posted stronger-than ...

M, +43% v. 2023; 4Q 2024 revenues of $77M, +31% v. 4Q 20232024 net income of $28M; Non-GAAP net income of $68M 4Q 2024 net ...

RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced ...

Individuals genetically deficient in IL-12/IL-23 are particularly vulnerable to disseminated infections from mycobacteria ...

Whether they increase the risk of infections with nontuberculous mycobacteria (NTM) is uncertain. Objectives To determine the effect of anti-TNF therapy and other anti-rheumatic drugs on the risk of ...

This follows the discontinuation of Spero’s Phase 2 program for a drug candidate aimed at treating nontuberculous mycobacterial infections. Despite this, Spero Therapeutics continues to work on ...

After hours: February 27 at 5:12:41 PM EST Loading Chart for INSM ...